Industry Updates for the Psychedelics World | Page 33 of 35

Psychedelics News

Industry

24 Dec 2021

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial

The company announced today the receipt of correspondence from the U....

By Microdose

Industry

22 Dec 2021

MindMed Provides Update on Phase 2b LSD Trial

It’s been a rough 6 months for most of the psychedelic medicine industry....

By Jason Najum

Industry

20 Dec 2021

Company Update: A Look at Mydecine Innovations Group

With the recent news of Mydecine securing capital for their upcoming trials, the company might finally be ready to make that next jump....

By Microdose

Industry

17 Dec 2021

MindMed Initiates Phase 2a LSD Trial

MindMed begins its Phase 2a trial using LSD to treat ADHD...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

14 Dec 2021

atai Life Sciences Added to NASDAQ Biotechnology Index

Atai announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021...

By Microdose

Industry

9 Dec 2021

Mydecine Secures Financing and Provides Company Update

Mydecine Secures Financing and Provides Company Update....

By Jason Najum

Industry

9 Dec 2021

GH Research Update: Financials, Business Update, and Trial Results

Now we have news of $280 million in cash on hand, and successful outcomes in a Phase 2 clinical trial using 5-MeO-DMT for treatment-resistant depression....

By Jason Najum

Industry

3 Dec 2021

Breaking News: MAPS and Vine VC Launch Innovative $70 Million Funding Structure

MAPS and Vine Ventures have created an innovative funding structure that will give MAPS access to $70 million in funds while allowing the organization to retain its non-profit status....

By Jason Najum

Industry

1 Dec 2021

Cybin Gets FDA Approval For New Phase 2 Trial

Following up on their recent run of solid news (led by very positive results from their new CYB-003 compound), Cybin has just announced that the FDA has authorized a Phase...

By Jason Najum

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result